Filtered By:
Condition: Heart Failure
Vaccination: Vaccines

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 45 results found since Jan 2013.

Chronic obstructive pulmonary disease.
Abstract The global prevalence of physiologically defined chronic obstructive pulmonary disease (COPD) in adults aged >40 yr is approximately 9-10 per cent. Recently, the Indian Study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis in Adults had shown that the overall prevalence of chronic bronchitis in adults >35 yr is 3.49 per cent. The development of COPD is multifactorial and the risk factors of COPD include genetic and environmental factors. Pathological changes in COPD are observed in central airways, small airways and alveolar space. The proposed pathogenesis of COPD includes pr...
Source: The Indian Journal of Medical Research - February 1, 2013 Category: Biomedical Science Authors: Vijayan VK Tags: Indian J Med Res Source Type: research

Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation
Conclusion The high AF detection performance of the MyDiagnostick, combined with the ease of use of the device, enables large screening programmes for detection of undiagnosed AF.
Source: Europace - August 29, 2014 Category: Cardiology Authors: Tieleman, R. G., Plantinga, Y., Rinkes, D., Bartels, G. L., Posma, J. L., Cator, R., Hofman, C., Houben, R. P. Tags: Atrial fibrillation Source Type: research

Beyond vascular inflammation-recent advances in understanding atherosclerosis.
Abstract Atherosclerosis is the most life-threatening pathology worldwide. Its major clinical complications, stroke, myocardial infarction, and heart failure, are on the rise in many regions of the world-despite considerable progress in understanding cause, progression, and consequences of atherosclerosis. Originally perceived as a lipid-storage disease of the arterial wall (Die cellularpathologie in ihrer begründung auf physiologische und pathologische gewebelehre. August Hirschwald Verlag Berlin, [1871]), atherosclerosis was recognized as a chronic inflammatory disease in 1986 (New Engl J Med 314:488-500, 1986)...
Source: Cellular and Molecular Life Sciences : CMLS - June 23, 2015 Category: Cytology Authors: Wolf D, Zirlik A, Ley K Tags: Cell Mol Life Sci Source Type: research

Developments in the management of Chagas cardiomyopathy.
Authors: Tanowitz HB, Machado FS, Spray DC, Friedman JM, Weiss OS, Lora JN, Nagajyothi J, Moraes DN, Garg NJ, Nunes MC, Ribeiro AL Abstract Over 100 years have elapsed since the discovery of Chagas disease and there is still much to learn regarding pathogenesis and treatment. Although there are antiparasitic drugs available, such as benznidazole and nifurtimox, they are not totally reliable and often toxic. A recently released negative clinical trial with benznidazole in patients with chronic Chagas cardiomyopathy further reinforces the concerns regarding its effectiveness. New drugs and new delivery systems, incl...
Source: Expert Review of Cardiovascular Therapy - February 17, 2016 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Flu vaccine may reduce risk of death for type 2 diabetes patients
( Imperial College London ) The flu vaccine may reduce the likelihood of being hospitalized with stroke and heart failure in people with type 2 diabetes, according to new research. The study, from scientists at Imperial College London, also found patients who received the influenza vaccination had a 24 per cent lower death rate in the flu season compared to patients who weren't vaccinated.
Source: EurekAlert! - Infectious and Emerging Diseases - July 25, 2016 Category: Infectious Diseases Source Type: news

Well: Flu Vaccine Has Added Benefits for People With Diabetes
People with Type 2 diabetes who got the flu vaccine had a lower risk of stroke and heart failure.
Source: NYT Health - July 27, 2016 Category: Consumer Health News Authors: NICHOLAS BAKALAR Tags: Diabetes Influenza Vaccination and Immunization Featured Live Source Type: news

Pneumonia in the Noninstitutionalized Older Population.
CONCLUSION: Pneumonia plays an important role in the medical care of non-institutionalized older people. With the aid of the predictors identified in this study, primary care physicians can identify patients at risk, smokers can gain additional motivation to quit, treatment compliance can be increased, and patients may become more willing to be vaccinated as recommended in the current guidelines. PMID: 27697144 [PubMed - in process]
Source: Deutsches Arzteblatt International - October 5, 2016 Category: Journals (General) Tags: Dtsch Arztebl Int Source Type: research

Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design
ConclusionThis is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular events in high risk individuals.Trial registration number:Clinicaltrials.govNCT02762851
Source: American Heart Journal - March 12, 2019 Category: Cardiology Source Type: research

Opportunistic screening for atrial fibrillation by clinical pharmacists in UK general practice during the influenza vaccination season: A cross-sectional feasibility study
ConclusionsThis study demonstrates that AF screening performed by GP practice –based pharmacists was feasible, economically viable, and positively endorsed by participants. Furthermore, diagnosis of AF by the clinical pharmacist using anSLECG was more sensitive and more specific than the use of pulse palpation alone. Future research should explore the key barriers preventing the adoption of national screening programmes.
Source: PLoS Medicine - July 16, 2020 Category: Internal Medicine Authors: Vilius Savickas Source Type: research

What Are the Main Acyanotic Congenital Heart Diseases?
Discussion Congenital heart diseases (CHD) are malformations of the heart and great vessels. It occurs in about 5-8/1000 live births. Cyanotic congenital heart disease is often noted perinatally because of cyanosis, respiratory distress and/or poor feeding or other distress type problems. A review can be found here. Acyanotic congenital heart disease (ACHD) can present at birth but often is seen in older children or adults unless the lesions are severe, especially obstructive lesions. Severe lesions may also cause cyanosis and distress type problems in patients also. Shunting lesions cause problems by diverting blood flo...
Source: PediatricEducation.org - August 17, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

SARS ‐CoV‐2 and hypertension
The objective of this review is to give an overview of the pathophysiological effects of the Coronavirus Disease 2019 (COVID-19) in relation to hypertension (HT), with a focus on the Renin –Angiotensin–Aldosterone System (RAAS) and the MAS receptor. HT is a multifactorial disease and a public health burden, as it is a risk factor for diseases like stroke, coronary artery disease, and heart failure, leading to 10.4 million deaths yearly. Blood pressure is regulated by the RAAS. The system consists of two counter-regulatory axes: ACE/ANG-II/AT1R and ACE2/ANG-(1-7)/MAS. The main regulatory protein in balancing the RAAS is...
Source: Physiological Reports - June 14, 2021 Category: Physiology Authors: Briyanth Ravichandran, Daniela Grimm, Marcus Kr üger, Sascha Kopp, Manfred Infanger, Markus Wehland Tags: REVIEW Source Type: research

COVID-19 Exposed the Faults in America ’s Elder Care System. This Is Our Best Shot to Fix Them
For the American public, one of the first signs of the COVID-19 pandemic to come was a tragedy at a nursing home near Seattle. On Feb. 29, 2020, officials from the U.S. Centers for Disease Control and Prevention (CDC) and Washington State announced the U.S. had its first outbreak of the novel coronavirus. Three people in the area had tested positive the day before; two of them were associated with Life Care Center of Kirkland, and officials expected more to follow soon. When asked what steps the nursing home could take to control the spread, Dr. Jeff Duchin, health officer for Seattle and King County, said he was working w...
Source: TIME: Health - June 15, 2021 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized Aging COVID-19 feature franchise Magazine TIME for Health Source Type: news

Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news